Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M . TYMLOS exits 2019 with 52% market share in new patients 1 , on track for market leadership in 2020. Radius delivers strong year-end balance sheet with $160M cash 2 balance and expects to achieve profitability
View HTML
Toggle Summary Radius Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that its senior executive management team will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:30 am PST at the Westin St.
View HTML
Toggle Summary Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)
WALTHAM, Mass. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio Breast Cancer Symposium, which will take place from December 10 – 14 in San
View HTML
Toggle Summary Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 50,000 shares of the Company’s common stock with a per
View HTML
Toggle Summary Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London
WALTHAM, Mass. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global Healthcare Conference in London, United Kingdom on Wednesday, November 20, 2019
View HTML
Toggle Summary Radius Health Announces Third Quarter 2019 Results and Corporate Update
TYMLOS U.S. net sales grew to $47M and is capturing half of anabolic new patient starts 1 Guidance for FY 2019 sales increased to $168-$172M (vs. $165-$170M prior) and year-end cash, cash equivalents and investments balance increased to over $130M (vs.
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019
WALTHAM, Mass. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019 . The Company will host a conference call and live audio webcast at 4:30 p.m.
View HTML
Toggle Summary Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting
WALTHAM, Mass. , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience, at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting, which will take
View HTML
Toggle Summary Radius Health to Participate in the Citi 14th Annual Biotech Conference and Morgan Stanley 17th Annual Global Healthcare Conference in September
WALTHAM, Mass. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2019 . Radius Health management will host meetings with investors at the Citi 14 th Annual Biotech Conference in Boston on September 5,
View HTML
Toggle Summary Radius Health Announces Second Quarter 2019 Operating Results
TYMLOS® U.S. net sales were $41.0 million in the second quarter of 201 9, an 81% growth over the second quarter of 2018. TYMLOS continued increasing its share of the U.S. anabolic osteoporosis market capturing an average of 35% total market share and 46% share in new patients in the second quarter
View HTML